PDCD1 and small cell lung carcinoma: Slulizumab is the first anti-PD-1 monoclonal antibody in the first-line treatment of ES-SCLC worldwide.340 In conclusion, PD-L1 inhibitors are more beneficial to patients with SCLC than PD-1 inhibitors.